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I. The Problem 
, 
Neural tube defects (NTD) is a collective term for a group of birth 
defects which include anencephaly, encephalocele and spina bifida. In 
California, the incidence of NTD is I. I per thousand live births. By type 
and incidence, NTD can be subgrouped as: 1 
Anencephaly 
Encephalocele 
Spina bifida 
0.5 / 1000 
0.08/1000 
0.5 / 1000 
Anencephaly is incompatible with life- the affected neonate succumbs 
within a few hours of birth. Encephalocele is rare and generally results in 
some degree of mental disability. 
Spina bifida will affect approximately 185 newborn infants in California 
each year. Successful treatment exists for most cases of even the worst 
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physical disability, and most of these children are not mentally impaired. 
NTD, therefore, is not a leading cause of morbidity and mortalit y for 
children in California; rather, it is a potentia ll y handicapping di sorder for 
which effective postnatal therapy has generally been reali 7.ed . 
The technology now exists which enables the detection of only eight y 
percent of neural tube defects during the middle of pregnancy. This 
technology consists of screening the se rum of their mothers for alpha-
fetoprotein during the 16th to the 18th week of pregnancy. Alpha-
fetoprotein is the fetal analogue of ad ult albumin, and it is usuall y e levated 
in both the maternal se rum and the amniotic fluid if the developing human 
is affected with an NTD or o mphalocele. Inte resting ly, the maternal se rum 
alpha-fetoprotein (MSAFP) is depressed in some insta nces when th e 
developing human has Down's syndrome. 
II. Informative Digest 
In 1982, Section 289.7 of the Health and Safety Code was amended. 
requiring the Department of Health Services to promulga te regulations 
governing the alpha-fetoprotein test kits that were soon to be approved for 
marketing by the FDA. The intent of the legislative mandate was to 
protect the public from unsc rupulous marketing by the private sector 
which could lead to inaccurate testing and misinterpretation of test 
results 2 The department fail ed to provide regulations . and the leg islature 
therefore amended the FY 1983 / 84 Budget Act requiring emergency 
regulations . It was never the int ent of the legislature to implement a 
mandatory statewide alpha-fetoprotein screening program. and this fact is 
appropriately demonstrated by the rejecti o n of the emergency legislation 
AB 1846 (Margolin) in 1985. 
Lori Andrews, J.D .. project director in medical law for the American 
Bar Foundation, questions whether such regulations can be responsive to 
public opinion: "If you're going to make policies that force peo ple to 
undergo medical services. should th e decisions be made i ~ a back room or 
in the legislature where all inte rests are heard 'l"l Nevertheless. the 
regulations were drafted in a "back room" fashion and subsequently 
implemented. contrary to leg islati ve intent. 
III. The Position of Professional Organizations 
In 1982, responding to the call to screen all pregna nt women for NTDs, 
the American College of Obstetrics and Gynecology (ACOG) stated: "The 
risks and costs appear to outweigh the advantages and the prog ram should 
not be implemented ."4 
Contrary to the misinformation which has been promulgated . the 
ACOG has never altered it s position. The American Medical Association 
(AMA) stands by its report by th e Council on Scientific Affairs which 
concluded: "Maternal serum alpha-fetoprotein screening of all pregnant 
women should not be advocated at this time ."5 
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The following discussion will clarify the reasons why the ACOG and the 
A M A hold this position. 
The Program 
In California, 370,000 women annually are in prenatal care by the 16th 
to the 18th week of pregnancy.6 Using available statistics7,8,9, the statewide 
program in California will work as is shown in Tables I and II. 
Neural Tube Defects 
The problem with the NTD screening program is the lack of reliability of 
the serum alpha-fetaprotein test. The test is falsely positive (that is , 
unaffected women will test as if their baby is affected) in 95 percent of the 
cases. IO More distressing to the DHS is the fact that the test is falsely 
negative (that is , infants with NTD who test as normal) in 22 percent of the 
cases. I I 
With unaffected pregnancies testing falsely positive, the level of 
maternal anxiety for those women participating has increased dra-
matically. This has already led participating physicians to conclude that 
the "California Alpha-Fetoprotein Screening Program should be halted or 
abolished altogether".!2 This verifies the warning by U.S. Surgeon General 
C. Everett Koop who, prior to the implementation of the program, 
warned: "A positive alpha-fetoprotein test can lead women to have 
abortions because they can have the impression that they are carrying a 
spina bifida child" .13 James N. Macri Ph.D. , director of the NTD 
Laboratory at the State University of New York at Stony Brook, noted 
that not all false-positive results can be eliminated so that there is a risk of 
aborting a normal fetus. 14 Furthermore, Leroy Walter Ph. D., of the 
Kennedy Institute's Center for Bioethics at Georgetown University, said 
that some women whose first MSAFP screening test results were positive 
were sufficiently frightened "that they went off and secured an abortion 
then and there ."1 5 This creates a dilemma for all public health sc reening 
programs. A proponent of this program, Prof. Joe Leigh ~impso n, head of 
the section of human genetics at Northwestern University, even worries 
that "unnecessary abortions are likely to occur ... potentially leading to a 
loss of public confidence in genetic screening".'" 
Since elevated MSAFP levels will lead to 6,263 amniocenteses per year 
in California (see Table I) , "the demand for chromosomal st udies of 
amniotic fluid fibroblasts [will] be greatly increased because, for legal 
reasons , it [will] be hazardous to perform amniocentesis without 
performing genetic studies".I!> 
Analysis of the data in Table I reveals that 323 developing humans will 
be identified as having an NTD. The alleged goal of the screening program 
is to detect affected infants so that appropriate life-saving surgical 
intervention can be delivered immediately upon birth. It is appropriate to 
determine the number of these affected infants who would require this 
intervention . 
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Referring to Section I of this report, almost one-half of those infants 
with NTDs will have a condition compatible with life: that is , 142 will have 
spina bifida cystica. According to Mitchell S. Golbus M . D., professor of 
obstetrics, gynecology and pediatrics at the University of California at San 
Francisco, the only malformation requiring immediate post-natal sterile 
surgical correction is uncovered meningomyelocele. 17 Eighty percent of all 
spina bifida cystica births consist of uncovered meningomyeloceles, and 25 
percent of these will be stillborn. 18 Thus, only 85 infants would have been 
live-born with an uncovered meningomyelocele . Can the cost of screening 
justify identifying these infants, especially since effective post-natal 
therapy antedates the implementation of the screening program? 
Omphalocele 
As mentioned, omphalocele can also be detected by an elevated 
MSAFP. This condition is rare: its incidence is only I :6000. 19 According to 
Dr. Golbus, only a ruptured omphalocele requires immediate post-natal 
sterile surgical correction;20 approximately 18.5 percent are ruptured. 21 
The sensitivity of the screening program is 73 percent. 22 Of the 35 affected 
infants detected by the California Alpha-Fetoprotein Screening Program, 
only six will have what Dr. Golbus defines as a surgical emergency- a 
ruptured omphalocele. This condition is almost always amenable to 
medical and surgical treatment after birth , leaving affected infants with no 
physical or mental disability. Late complications have been virtually 
nonexistent. 23 
Down's Syndrome 
The overall incidence of Down's Syndrome is I :800 live births. 24 A low 
M SAFP suggests its presence; however , the sensitivity of the test is only 20 
percent25 , and the test is falsely positive in over 97 perce pt of the women 
tested. 26 False positive screening tests are obtained with even greater 
frequency than is the case in neural tube defect screening. Analysis of the 
data in Ta ble II indica tes that 92 women will be determined to be carrying 
infants with Down's syndrome by the California Alpha-Fetoprotein 
Screening Program. There is no current surgical imperative to identify 
these infants antenatally other than for the purpose of abortion. 
V. Data Analysis 
The stated goal of the California Alpha-Fetoprotein Screening Program 
is to enhance the survival chances of affected infants. Proponents argue 
that this can only be done by detecting affected infants antenatally in order 
to have a surgical team present at the instant of delivery. immediately 
repairing the neural tube defect or ruptured omphalocele. The following 
analyses show that the purported goal of the program is not substantiated. 
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Cost Analysis 
The cost of the techniqal aspects of the NTD screening program itself, as 
determined from Table I, is : 
A. $5,550,000 
B. 274,725 
C. 1,571 ,427 
D. 5, 166,975 
G. 444,000 
H. 2,095,236 
I. 6,043,950 
Total: $21,151 ,313 
The costs of the technical aspects of the program for a different level of 
utilization (or for other areas in the United States where such a program 
might be proposed) can be estimated by: 
cost($) = (57.16)x , 
where x = the number of women screened. 
This does not include program costs . For example, it is estimated that 
one genetic counselor is required for every 150 individuals identified at 
risk .27 Referring to Tables I and II , (Levels D and I, respectively) , it can be 
seen that the California program would require up to 91 full-time genetic 
counselors. The program will have to rent facilities at each of the 19 
regional centers throughout the state . In addition , it will have to fund the 
necessary support staff. A proposed program budget is outlined in Table 
III. 
The total program cost (excluding $743,850 for abortions) of the 
proposed screening program would therefore be $28,228,566. For 
different levels of utilization , the program costs can be estimated by: 
, 
Program cost($) = 2778545 + (67.686)x, 
where x = the number of women screened. 
Assuming the unlikely event of full participation, it will cost an average 
of $76.29 for each woman screened. Claiming to be self-supporting, the 
California Alpha-Fetoprotein Screening Program proposes to charge $40 
for every woman who participates. This $36.29 per woman discrepancy 
($13.4 M) will have to be compensated by the state of California, Medi-Cal 
(Medicaid), and third party insurance carriers. Underutilization of the 
program will increase the differential, and it is therefore not surprising that 
the Screening Program has already petitioned the legislature for 
operational funding. The FY 86 / 87 Budget Act originally authorized 
$7M , but this was augmented to $12M as the program was initiated. 
Medi-Cal is authorized to pay for the fee for participating women covered 
under California's Medicaid program. 28 
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Cost:Benefit Analysis 
The stated goal of the program is "to detect those infants who would 
require immediate surgery". The California Alpha-Fetoprotein Screening 
Program will detect 91 developing humans with an uncovered 
meningomyelocele or ruptured omphalocele at a total cost of 
$28,228,566- that is, $310,204 for each case identified. Since it has been 
estimated that the lifetime medical cost of care for each person with spina 
bifida is $80,00029, it is obvious that the program is not justifiable on a cost: 
benefit analysis. 
Benefit:Risk Analysis 
The human cost of this proposed program is extremely objectionable. 
For every 10 developing humans identified with spina bifida cystica, 
omphalocele or Down's syndrome, 18 who are affected will be missed and 
18 normal unafFecled ones will he killed. (268 affected ones; 469 normal 
developing humans killed - see Tables I and II). This analysis does not 
even address the enormous public health consequences for the 783 women 
undergoing late mid-trimester abortions (see below) JO Obviously , the 
program is not designed to enhance the well-being of affected infants; 
rather, it is a program of eugenics which institutionalizes discrimination 
against handicapped children. 
VI. Goal Analysis 
What is the real purpose of identifying these developing humans? 
Doctor Berkowitz of the Mount Sinai Medical Center in New York says 
that such a program exists so that "a diagnosis can be made prior to the 
time when pregnancy can legally be terminated (sic)". 31 The Hastings 
Center concludes that the screening program "does detect a serious 
condition ... but the condition cannot be arrested or treated except by 
aborting the affected fetus."32 Even the California Department of Health 
Services concurs when it states: "As the screening program is implemented 
it is estimated that the number of cases diagnosed at birt ~ should drop by 
up to 80%. "33 Dr. George Cunningham, Chief of the Genetic Disease 
Branch in the California Department of Health Services, states that he 
expects 90 percent of women with abnormal screening to obtain 
abortions34 even though their children's disabilities would not usually be 
severe. 
There is no in ulero treatment for the affected ones. The California 
Department of Health Services, in speaking of "prevention strategies", is 
using a euphemism to cover the destruction of these developing humans in 
Ulero. The program is not even an efficient popUlation purification 
program: it must be distressing to the eugenicists in the DHS that this 
Screening Program will actually miss 472 affected infants. Since the cost of 
discovery for each case (including aneuploidy) is at least $108,106 and 
since there is no in Ulero treatment, should not these funds be used to care 
for the affected infants rather than to destroy them? 
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VII. Ethical Implications 
The California Alpha-Fetoprotein Screening Program raises ethical 
concerns in at least four areas. 
Participation by Mandate 
The regulations make it mandatory for physicians to participate in this 
"search and destroy" program which is part of the "prevention strategy" of 
the Department of Health Services. It is unethical to mandate screening 
tests for conditions which are not treatable. It is a violation of conscience 
for many physicians to participate in this program. 
Participation by Coercion 
If an expectant mother decides not to participate, she must sign this 
waiver: "No. I refuse to have the alpha-fetoprotein blood screening test 
done . I understand and accept the consequences of this decision ." If she 
agrees to participate, she signs: "Yes. I request that blood be drawn for the 
alpha-fetoprotein screening test."3S The bias is obvious, and its intent is to 
frighten the expectant mother into participation. 
Discrimination 
As discussed in the preceding section, the California Alpha-Fetoprotein 
Screening Program institutionalizes discrimination against handicapped 
children. 
Restriction of Utilization 
The Department of Health Services has implemented regulations that 
restrict MSAFP testing to the California Alpha-Fetoprotein Screening 
Program, at a cost of $40 to every woman participating. The test could be 
performed in the private sector for approximately $7. Expectant mothers, 
the majority of whom are opposed to it, are thus being coerced to support a 
program which promotes abortion. ' 
Conclusion 
The California Alpha-Fetoprotein Screening Program must be seen for 
what it really is: a eugenic population control program masquerading as an 
advocacy program for children with disabilities. More normal unaffected 
children will be killed than will be the number of abnormal ones identified 
by this program. The morality, motives and tactics of the proponents of 
this program need to be fully exposed. It is an ethical as well as a civil rights 
violation to force expectant mothers and their physicians to participate in 
the California Alpha-Fetoprotein Screening Program. 
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TABLE I 
NTD Screening Program 
L 
E 
V 2 3 4 5 6 
E 
L 
# of 
women test cost ($) % abnormal # abnormal comments 
A. 370,000 MSAFP @15 5 18,500 1% loss 2° 
maternal 
anxiety 
B. 18,315 MSAFP @15 60 10,989 
C. 10,989 US-I" @143 57 6,263 
O. 6.263 US-II h @825 5 323 10/{: loss 2° 
amnio' to amnio 
E. 323 O&E @950 plus 35 with 
omphalo-
cele 
Note: 185 developing humans voluntarily aborted at Level A; 
63 succumbed at Level 0 solely as complications of the screening 
program. 
Note: since false negative rate = 220/(·, 95 with NTO missed: # missed = 
([05+(06) (04) (Ol)] / (l-FNR»- 05 = (323+3) / (0.78) - 323 = 95 
a = level I ultrasound at $143 per Grossmont Hospital. La Mesa. CA 
b = level II ultrasound with amniocentesis for alpha -fetoprotein at $375 
per the Fetal Diagnosis and Treatment Center (FOTC). UCSO 
c = an additional $450 for karyotyping per the FOTC. UCSO 
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TABLE II 
Down's Syndrome Screening Program 
L 
E 
V 2 3 
E 
L 
# of 
women test cost {$} 
F. 370,000 MSAFP @15 
G. 29,600 MSAFP @15 
H. 14,652 US-I" 
I. 7,326 US-II " 
amnio' 
J. 92 D&E 
@143 
@825 
@950 
4 5 
% abnormal # abnormal 
8 29,600 
50 14,800 
50 7,326 
1.25 92 
6 
comments 
I % fetal loss 
2° anxiety 
1% loss 2° 
to amnio 
Note: 148 developing humans voluntarily aborted at Level G; 
73 succumbed at Level I solely as complications of the screening 
program. 
Note: since false negative rate = 80% , 373 with Down's missed: 
# missed = ( [15+(16) (14) (ll)] / (I-FNR) ) - 15' = (92+1) / (0.20) 
- 92 = 373 
a = level I ultrasound at $143 per Grossmont Hospital, La Mesa, CA 
b = level II ultrasound with amniocentesis for alpha-fetoprotein at $375 
per the Fetal Diagnosis and Treatment Center (FDTC), UCSD 
c = $450 for karyotyping per the FDTC, UCSD 
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TABLE III 
Technical/Operational Program Budget 
Item 
Salaries 
Program Director 
Deputy Director 
Admin. As~jstant 
Genetic Coun. (9\) 
Cler. Assist. (19) 
Secretarial (19) 
Data Entry Clerk 
Temporary Assist. 
Regional Cnt. liaison 
Fringe Benefits 
Tech Costs (Tables I & II) 
Travel 
Other Direct Costs 
Telephone 
Postage 
Duplicating 
Printing 
Office supplies 
Computer costs 
Facility leasing 
Indirect Costs 
TOTAL COSTS 
Total 
$ 59,565 
$43,875 
22,530 
2,936,678 
293,825 
360,000 
31,290 
10,000 
5,265 
1,260,050 
21 , 151,313 
24,000 
90,000 
30,000 
90,000 
120,000 
33,020 
125,000 
275,000 
890,000 
$28,228,566 
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